Lenvatinib mesylate（Cat No.:I046128）is an oral multi-kinase inhibitor targeting VEGFR1–3, FGFR1–4, PDGFRα, RET, and KIT, developed for cancer therapy. By blocking angiogenesis and tumor growth pathways, it reduces vascular supply and proliferation of cancer cells. Clinically, lenvatinib mesylate is approved for hepatocellular carcinoma, thyroid cancer, and renal cell carcinoma, often used alone or in combination with other agents like pembrolizumab. Its unique activity profile offers efficacy across multiple tumor types. Research continues to explore its applications in solid tumors and resistance mechanisms in targeted oncology therapy.